+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020

  • ID: 5024737
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 69 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Biken Co Ltd
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • MORE
Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 7, 7, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biken Co Ltd
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Haemophilus influenzae Type B Infections - Overview
  • Haemophilus influenzae Type B Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Haemophilus influenzae Type B Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development
  • Beijing Minhai Biotechnology Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • Hilleman Laboratories Pvt Ltd
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Liaoning Chengda Co., Ltd.
  • Novo Medi Sciences Pvt Ltd
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Tuck-More Biotechnology Co Ltd
  • Vaxxilon AG
  • Yisheng Biopharma Co Ltd
  • Haemophilus influenzae Type B Infections - Drug Profiles
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BK-1310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • haemophilus influenza B vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • haemophilus influenzae [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Haemophilus influenzae B vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Haemophilus influenzae B vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Haemophilus influenzae B vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-370 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBVD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LT-Hib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Haemophilus influenzae Type B Infections - Dormant Projects
  • Haemophilus influenzae Type B Infections - Discontinued Products
  • Haemophilus influenzae Type B Infections - Product Development Milestones
  • Featured News & Press Releases
  • Jan 07, 2019: Biomedical Sciences researcher gets $3.26 million grant to develop universal flu vaccine
  • Jun 24, 2015: Hilleman Laboratories’ preclinical trial report on Hib vaccine offers hope to millions of children
  • Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
  • Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India
  • May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Biken Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Biological E Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by CanSino Biologics Inc, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by KM Biologics Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by LG Chem Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Liaoning Chengda Co., Ltd., H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Serum Institute of India Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Tuck-More Biotechnology Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Vaxxilon AG, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Dormant Projects, H1 2020
  • Haemophilus influenzae Type B Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Haemophilus influenzae Type B Infections - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Beijing Minhai Biotechnology Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • Hilleman Laboratories Pvt Ltd
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Liaoning Chengda Co., Ltd.
  • Novo Medi Sciences Pvt Ltd
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Tuck-More Biotechnology Co Ltd
  • Vaxxilon AG
  • Yisheng Biopharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll